122 related articles for article (PubMed ID: 17848087)
1. Depletion of folate-receptor-positive macrophages leads to alleviation of symptoms and prolonged survival in two murine models of systemic lupus erythematosus.
Varghese B; Haase N; Low PS
Mol Pharm; 2007; 4(5):679-85. PubMed ID: 17848087
[TBL] [Abstract][Full Text] [Related]
2. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
3. Folate-targeted hapten immunotherapy of adjuvant-induced arthritis: comparison of hapten potencies.
Yi YS; Ayala-López W; Kularatne SA; Low PS
Mol Pharm; 2009; 6(4):1228-36. PubMed ID: 19374407
[TBL] [Abstract][Full Text] [Related]
4. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential.
Lu Y; Sega E; Leamon CP; Low PS
Adv Drug Deliv Rev; 2004 Apr; 56(8):1161-76. PubMed ID: 15094213
[TBL] [Abstract][Full Text] [Related]
5. Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy.
Sega EI; Lu Y; Ringor M; Leamon CP; Low PS
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):559-66. PubMed ID: 18411004
[TBL] [Abstract][Full Text] [Related]
6. Increased uptake of folate conjugates by activated macrophages in experimental hyperlipemia.
Antohe F; Radulescu L; Puchianu E; Kennedy MD; Low PS; Simionescu M
Cell Tissue Res; 2005 May; 320(2):277-85. PubMed ID: 15714274
[TBL] [Abstract][Full Text] [Related]
7. The immune response to cell death in SLE.
Pisetsky DS
Autoimmun Rev; 2004 Nov; 3(7-8):500-4. PubMed ID: 15546797
[TBL] [Abstract][Full Text] [Related]
8. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
Low PS; Henne WA; Doorneweerd DD
Acc Chem Res; 2008 Jan; 41(1):120-9. PubMed ID: 17655275
[TBL] [Abstract][Full Text] [Related]
9. Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus.
Bubier JA; Bennett SM; Sproule TJ; Lyons BL; Olland S; Young DA; Roopenian DC
Ann N Y Acad Sci; 2007 Sep; 1110():590-601. PubMed ID: 17911475
[TBL] [Abstract][Full Text] [Related]
10. Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients.
van der Heijden JW; Oerlemans R; Dijkmans BA; Qi H; van der Laken CJ; Lems WF; Jackman AL; Kraan MC; Tak PP; Ratnam M; Jansen G
Arthritis Rheum; 2009 Jan; 60(1):12-21. PubMed ID: 19116913
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosus-like syndrome.
Han B; Moore PA; Wu J; Luo H
Arthritis Rheum; 2007 Nov; 56(11):3748-58. PubMed ID: 17968950
[TBL] [Abstract][Full Text] [Related]
12. Optimization of Folate-Targeted Immunotherapy for the Treatment of Experimental Arthritis.
Varghese B; Paulos C; Low PS
Inflammation; 2016 Aug; 39(4):1345-53. PubMed ID: 27206918
[TBL] [Abstract][Full Text] [Related]
13. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
Steinmetz OM; Turner JE; Paust HJ; Lindner M; Peters A; Heiss K; Velden J; Hopfer H; Fehr S; Krieger T; Meyer-Schwesinger C; Meyer TN; Helmchen U; Mittrücker HW; Stahl RA; Panzer U
J Immunol; 2009 Oct; 183(7):4693-704. PubMed ID: 19734217
[TBL] [Abstract][Full Text] [Related]
14. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis.
Taylor RP; Lindorfer MA
Nat Clin Pract Rheumatol; 2007 Feb; 3(2):86-95. PubMed ID: 17299446
[TBL] [Abstract][Full Text] [Related]
15. Impaired clearance of dying cells in systemic lupus erythematosus.
Gaipl US; Voll RE; Sheriff A; Franz S; Kalden JR; Herrmann M
Autoimmun Rev; 2005 Apr; 4(4):189-94. PubMed ID: 15893710
[TBL] [Abstract][Full Text] [Related]
16. The role of iNKT cells in the immunopathology of systemic lupus erythematosus.
Gabriel L; Morley BJ; Rogers NJ
Ann N Y Acad Sci; 2009 Sep; 1173():435-41. PubMed ID: 19758183
[TBL] [Abstract][Full Text] [Related]
17. Macrophage subpopulations in systemic lupus erythematosus.
Orme J; Mohan C
Discov Med; 2012 Feb; 13(69):151-8. PubMed ID: 22369974
[TBL] [Abstract][Full Text] [Related]
18. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease.
Fairhurst AM; Wandstrat AE; Wakeland EK
Adv Immunol; 2006; 92():1-69. PubMed ID: 17145301
[TBL] [Abstract][Full Text] [Related]
19. CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus.
Kuhn A; Beissert S; Krammer PH
Arch Dermatol Res; 2009 Jan; 301(1):71-81. PubMed ID: 18985367
[TBL] [Abstract][Full Text] [Related]
20. Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus.
Kavai M; Szegedi G
Autoimmun Rev; 2007 Aug; 6(7):497-502. PubMed ID: 17643939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
